- Home
- DQ vs OPK Comparison
DQ vs OPK Comparison
Compare DQ & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DQ | OPK |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 877.0M | 1.0B |
| IPO Year | 2010 | 2011 |
Fundamental Metrics
Financial Performance| Metric | DQ | OPK |
|---|---|---|
| Price | $12.31 | $1.73 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $28.91 | $1.60 |
| AVG Volume (30 Days) | 782.6K | ★ 2.5M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $606,879,000.00 |
| Revenue This Year | $69.82 | N/A |
| Revenue Next Year | $34.34 | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.17 | $0.98 |
| 52 Week High | $36.59 | $1.73 |
Technical Indicators
Market Signals| Indicator | DQ | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 68.13 |
| Support Level | $11.47 | $1.12 |
| Resistance Level | $12.55 | $1.73 |
| Average True Range (ATR) | 0.43 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 42.19 | 87.50 |
Price Performance
Historical ComparisonAbout DQ DAQO New Energy Corp.
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.